Interdigitating Reticulum Cell Sarcoma Positive immunohistochemistry for HLA-DR and two other activation antigens,

C S Papadimitriou1, M C Bai1, D G Stephanou1

  • 1a Departments of Pathology, School of Medicine, University of Ioannina, Ioannina, Greece.

Leukemia & Lymphoma
|July 29, 2016
PubMed

Insights

This case study details a rare interdigitating reticulum cell sarcoma in lymph nodes. Immunophenotypic analysis identified key protein and antigen markers, including simultaneous positivity for CD30, HLA-DR, and IL2R activation antigens.

Area of Science:

  • Hematology
  • Oncology
  • Immunopathology

Background:

  • Interdigitating reticulum cell (IDRC) sarcoma is a rare neoplastic proliferation of lymph nodes.
  • Accurate diagnosis relies on comprehensive immunophenotypic analysis.

Purpose of the Study:

  • To report a rare case of IDRC sarcoma in a 46-year-old male patient.
  • To characterize the immunophenotype of neoplastic cells in IDRC sarcoma.
  • To discuss the significance of co-expression of activation antigens.

Main Methods:

  • Extensive immunophenotypic analysis was performed on paraffin and frozen lymph node sections.
  • Utilized a panel of antibodies targeting protein S-100 and various cell surface antigens (CD1, HLA-DR, CD4, CD25/IL2R, CD30/Ki-1).

Main Results:

  • Neoplastic cells showed positivity for protein S-100 and antigens CD1, HLA-DR, CD4, CD25 (IL2R), and CD30 (Ki-1).
  • Observed simultaneous positivity for the activation antigens CD30, HLA-DR, and IL2R.
  • This co-expression pattern is typically seen in Hodgkin's disease.

Conclusions:

  • The immunophenotype of this IDRC sarcoma case provides valuable diagnostic information.
  • The co-expression of CD30, HLA-DR, and IL2R highlights potential shared pathways with Hodgkin's disease.
  • Further research may elucidate the pathobiology of IDRC sarcoma.

Related Concept Videos